Vavricka John
SEC insider (Form 3/4/5 filer). CIK 0001829630. Chief Commercial Officer at Atea Pharmaceuticals, Inc. (AVIR). 6 reported Form 4/5 transactions since Sep 2024; latest on Jan 31, 2026. Located in BOSTON, MA.
Companies Vavricka John has filed insider reports for
- Atea Pharmaceuticals, Inc. (AVIR): Officer, Chief Commercial Officer
Vavricka John
CIK: 0001829630
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Atea Pharmaceuticals, Inc.
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Jan 31, 2026AVIR
Atea Pharmaceuticals, Inc.
ExerciseDirect42.1K shares- - Jan 31, 2026AVIR
Atea Pharmaceuticals, Inc.
Tax PaymentDirect11.6K shares at avg. $4.24$49K - Jan 31, 2026AVIR
Atea Pharmaceuticals, Inc.
AwardDirectStock Option (Right to Buy)
119.5K shares- - Jan 31, 2025AVIR
Atea Pharmaceuticals, Inc.
ExerciseDirect33.3K shares- - Jan 31, 2025AVIR
Atea Pharmaceuticals, Inc.
AwardDirect8.8K shares- - Jan 31, 2025AVIR
Atea Pharmaceuticals, Inc.
Tax PaymentDirect11.5K shares at avg. $3.06$35K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jan 31, 2026 | AVIR Atea Pharmaceuticals, Inc. | Exercise | 42,083 | - | $0 | Direct |
| Jan 31, 2026 | AVIR Atea Pharmaceuticals, Inc. | Tax Payment | 11,570 | $4.24 | $49,057 | Direct |
| Jan 31, 2026 | AVIR Atea Pharmaceuticals, Inc. | Award Stock Option (Right to Buy) | 119,520 | - | - | Direct |
| Jan 31, 2025 | AVIR Atea Pharmaceuticals, Inc. | Exercise | 33,333 | - | - | Direct |
| Jan 31, 2025 | AVIR Atea Pharmaceuticals, Inc. | Award | 8,750 | - | - | Direct |
| Jan 31, 2025 | AVIR Atea Pharmaceuticals, Inc. | Tax Payment | 11,517 | $3.06 | $35,242 | Direct |
1-6 of 6 transactions